Komori
Seiren (3569) · RiskRestated

Decline in Orders for Medical Products Following Drug-Price Revisions

First written in FY2018-Q1. 9 of 10 entries say "Restated". Latest entry: FY2020-Q3.

10entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q1 – FY2020-Q32017: 220172018: 320182019: 420192020: 12020
Same theme, other companies
Market and earnings impact on the pharmaceutical business from drug price revisions, healthcare system changes and pricing policy changesA theme 88 companies write about · 104 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.

47 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 88 companies compared. The sentences above are computed from all 88.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3RestatedAnnual report

    「In the medical materials field, customer development for high-value-added products leveraging KB Seiren Co., Ltd.'s Espansione® specialty yarn and the Group's integrated capabilities progressed, expanding the customer base. However, the impact of drug price revisions and other factors led to a decline in sales of certain medical materials.」

    The company continues to report a situation in which sales of certain medical materials are declining due to drug price revisions and other factors.
  2. FY2020-Q2RestatedAnnual report

    「The impact of drug price revisions and other factors led to a decline in sales among certain medical products.」

    The company continues to report a decline in sales among certain medical products due to drug price revisions and other factors.
  3. FY2020-Q1RestatedAnnual report

    「In the medical materials field, sales of differentiated products leveraging the Group's integrated capabilities, including KB Seiren Co., Ltd.'s Espansione® specialty yarn, increased. However, the impact of drug price revisions and other factors led to a decline in sales among certain medical products.」

    The company continues to report a situation in which sales of certain medical products are declining due to drug price revisions and other factors.
  4. FY2019RestatedAnnual report

    「In the medical materials field, sales of differentiated products leveraging the Group's integrated capabilities, centered on KB Seiren Co., Ltd.'s Espansione® specialty yarn, increased. However, the impact of drug price revisions and other factors led to a decline in sales among certain medical products.」

    The company continues to report a decline in sales among certain medical products due to drug price revisions and other factors.
  5. FY2019-Q3RestatedAnnual report

    「In the medical materials field, sales of differentiated products leveraging the Group's integrated capabilities, centered on KB Seiren Co., Ltd.'s specialty yarns, increased. However, the impact of drug price revisions and other factors led to a decline in sales among certain medical products.」

    The company continues to report a decline in sales among certain medical products due to drug price revisions and other factors.
  6. FY2019-Q2RestatedAnnual report

    「In the medical materials field, sales of differentiated products leveraging the Group's integrated capabilities, centered on KB Seiren Co., Ltd.'s specialty yarns, increased. However, the impact of drug price revisions and other factors led to a decline in sales among certain medical products.」

    The company continues to report a decline in sales among certain medical products due to drug price revisions and other factors.
  7. FY2019-Q1RestatedAnnual report

    「In the medical materials field, sales of differentiated products leveraging the Group's integrated capabilities, centered on KB Seiren Co., Ltd.'s specialty yarns, increased. However, the impact of drug price revisions led to a decline in sales among certain medical products.」

    The company continues to report a decline in sales among certain medical products due to the impact of drug price revisions.
  8. FY2018-Q3RestatedAnnual report

    「In the medical materials field, sales of differentiated products leveraging the Group's integrated capabilities, including KB Seiren Co., Ltd.'s differentiated yarns, increased. However, the impact of drug price revisions led to a decline in orders for existing products among certain medical products.」

    The company continues to report a decline in orders for existing products among certain medical products due to the impact of drug price revisions.
  9. FY2018-Q2RestatedAnnual report

    「In the materials field, sales of differentiated products leveraging the Group's integrated capabilities, including KB Seiren Co., Ltd.'s differentiated yarns, increased. However, the impact of drug price revisions led to a decline in orders for existing products among certain medical products.」

    The company continues to report a decline in orders for existing products among certain medical products due to the impact of drug price revisions.
  10. FY2018-Q1First statedAnnual report

    「Existing-product orders for some medical products declined because of the impact of drug-price revisions.」

    The impact of drug-price revisions led to an actual decline in orders for some existing medical products.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Seiren yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Decline in Orders for Medical Products Following Drug-Price Revisions | SEIREN CO.,LTD. (3569) | Komori